Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

This study is investigating whether dapagliflozin — a medication commonly used for diabetes and heart failure — can improve heart function and metabolism in people with chronic kidney disease (CKD) who also have early, silent heart failure (where the heart is stiff but still pumps normally), without having diabetes themselves. **You may be eligible if...** - You are over 18 with chronic kidney disease (moderate severity: estimated kidney filtration rate between 25-60 mL/min) - You have signs of early heart stiffness (diastolic dysfunction) detected on an echocardiogram or exercise test, but have not been diagnosed with clinical heart failure yet - You are on stable kidney/heart medications (diuretics and/or ACE inhibitor or ARB) **You may NOT be eligible if...** - You have diabetes (Type 1 or Type 2) - You are already taking an SGLT2 inhibitor - You have significant valve disease, uncontrolled blood pressure, or active cancer - You have had a heart procedure (stenting or bypass surgery) in the last 6 months - You are pregnant - You have a history of repeated urinary tract infections Talk to your doctor to see if this trial is right for you.